MTOR and malignant peripheral nerve sheath tumor: Combined targeting of the PI3K/AKT/mTOR pathway with the dual mTORC1 and mTORC2 inhibitor, AZD8055 and the MAPK pathway with the MEK inhibitor, PD0325901 was effective to synergistically inhibit cell growth in NF1-associated MPNST and NF1-derived Primary Schwann cells.